Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dibromochloropropane (DBCP) is a synthetic halogenated hydrocarbon pesticide, historically used as a soil fumigant against nematodes in agriculture. It is a dense yellow liquid, highly lipophilic and persistent in the environment, with a high mobility in soil and low potential for bioconcentration. DBCP is metabolized primarily in the liver via cytochrome P450 enzymes and glutathione S-transferases, forming cytotoxic metabolites that can bind covalently to DNA and cause single-strand breaks, particularly in testicular seminiferous tubules. Its main toxicity mechanism is gonadotoxicity—decreasing sperm mobility and spermatogenesis, causing testicular atrophy, and producing mutagenic and carcinogenic effects. Widespread use began in the 1950s, leading to regulatory bans due to its adverse health effects, including cancer and infertility[3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dibromochloropropane.